Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$392.81 - $485.53 $58,528 - $72,343
-149 Reduced 23.5%
485 $227,000
Q1 2024

May 14, 2024

SELL
$407.69 - $446.08 $80,722 - $88,323
-198 Reduced 23.8%
634 $265,000
Q3 2023

Nov 13, 2023

SELL
$338.18 - $362.46 $12,512 - $13,411
-37 Reduced 4.26%
832 $289,000
Q2 2023

Aug 11, 2023

SELL
$314.42 - $351.91 $43,075 - $48,211
-137 Reduced 13.62%
869 $305,000
Q1 2023

May 12, 2023

SELL
$283.23 - $323.1 $141,898 - $161,873
-501 Reduced 33.24%
1,006 $316,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $164,026 - $184,529
-574 Reduced 27.58%
1,507 $435,000
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $212,765 - $237,396
-777 Reduced 27.19%
2,081 $603,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $84,820 - $105,610
-361 Reduced 11.21%
2,858 $805,000
Q1 2022

May 13, 2022

SELL
$221.42 - $260.97 $15,277 - $18,006
-69 Reduced 2.1%
3,219 $840,000
Q4 2021

Feb 11, 2022

SELL
$177.01 - $223.45 $11,505 - $14,524
-65 Reduced 1.94%
3,288 $722,000
Q3 2021

Nov 12, 2021

SELL
$181.39 - $202.99 $302,558 - $338,587
-1,668 Reduced 33.22%
3,353 $608,000
Q2 2021

Aug 13, 2021

SELL
$187.49 - $221.1 $384,729 - $453,697
-2,052 Reduced 29.01%
5,021 $1.01 Million
Q1 2021

May 14, 2021

BUY
$207.02 - $241.31 $121,106 - $141,166
585 Added 9.02%
7,073 $1.52 Million
Q4 2020

Feb 12, 2021

BUY
$207.01 - $276.09 $492,683 - $657,094
2,380 Added 57.94%
6,488 $1.53 Million
Q3 2020

Nov 13, 2020

BUY
$255.65 - $303.1 $512,833 - $608,018
2,006 Added 95.43%
4,108 $1.12 Million
Q2 2020

Aug 13, 2020

SELL
$225.48 - $295.8 $462,910 - $607,277
-2,053 Reduced 49.41%
2,102 $610,000
Q1 2020

May 14, 2020

BUY
$199.77 - $247.81 $492,632 - $611,099
2,466 Added 146.0%
4,155 $989,000
Q4 2019

Feb 13, 2020

BUY
$166.71 - $223.91 $281,573 - $378,183
1,689 New
1,689 $370,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Fort, L.P. Portfolio

Follow Fort, L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Fort, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Fort, L.P. with notifications on news.